Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2075849 | 0.98 | CYP1A2 (0.49) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 | |
| SCHEMBL485158 | 0.94 | CYP1A2 (0.49) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 | |
| Trifluoroacetic Acid SCHEMBL15571773 | 0.93 | CYP1A2 (0.44) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 | |
| SCHEMBL484311 | 0.90 | CYP11B2 (0.49) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 | |
| SCHEMBL484585 | 0.90 | USP2 (0.46) | CYP1A2USP2SMN1; SMN2GPR119ACACB | |
| Hydrochloric Acid SCHEMBL349978 | 0.89 | CYP11B2 (0.48) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL896891 | 0.89 | USP2 (0.45) | CYP1A2USP2SMN1; SMN2GPR119ACACB | |
| SCHEMBL346995 | 0.88 | USP2 (0.56) | CYP1A2USP2SMN1; SMN2GPR119CYP2D6 | |
| Oxalic Acid SCHEMBL31368523 | 0.86 | CYP11B2 (0.46) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 | |
| SCHEMBL2870337 | 0.85 | L3MBTL3 (0.44) | CYP1A2USP2SMN1; SMN2GABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661529-A | Synthesis method of 3, 9-diazaspiro [5.5] undecane-3-tert-butyl formate | 上海馨远医药科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20250066325-A1 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | THE BROAD INSTITUTE, INC. | 2025-02-27 | — | — | US | claimed |
| EP-4426687-A1 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | The Brigham & Women's Hospital, Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| WO-2023081400-A9 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023081400-A1 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| JP-4726238-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | claimed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| EP-1660491-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | claimed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | claimed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | LTA4H, LTB4R, LTC4S | CYP1A2 682/4885USP2 1831/4885SMN1; SMN2 4712/4885 |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | CYP1A2 1031/4885USP2 3308/4885SMN1; SMN2 2349/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | CYP1A2 2109/4885USP2 642/4885SMN1; SMN2 4268/4885 |
| US-20250066325-A1 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | FKBP14, FKBP3, FKBP2 | CYP1A2 4336/4885USP2 618/4885SMN1; SMN2 4071/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | CYP1A2 1019/4885USP2 1794/4885SMN1; SMN2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.